Literature DB >> 16449632

Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesis.

James DeGregori1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449632      PMCID: PMC1367209          DOI: 10.1128/MCB.26.4.1165-1169.2006

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


× No keyword cloud information.
  52 in total

1.  E2F: a link between the Rb tumor suppressor protein and viral oncoproteins.

Authors:  J R Nevins
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

2.  Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes.

Authors:  P Raychaudhuri; S Bagchi; S H Devoto; V B Kraus; E Moran; J R Nevins
Journal:  Genes Dev       Date:  1991-07       Impact factor: 11.361

3.  Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer.

Authors:  R Gope; M L Gope
Journal:  Mol Cell Biochem       Date:  1992-03-25       Impact factor: 3.396

4.  The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression.

Authors:  A Borg; Q X Zhang; P Alm; H Olsson; G Sellberg
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

Review 5.  Tumor suppressor genes.

Authors:  P W Hinds; R A Weinberg
Journal:  Curr Opin Genet Dev       Date:  1994-02       Impact factor: 5.578

6.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.

Authors:  J M Horowitz; S H Park; E Bogenmann; J C Cheng; D W Yandell; F J Kaye; J D Minna; T P Dryja; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours.

Authors:  J M Varley; J Armour; J E Swallow; A J Jeffreys; B A Ponder; A T'Ang; Y K Fung; W J Brammar; R A Walker
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

8.  Inhibition of ras-induced proliferation and cellular transformation by p16INK4.

Authors:  M Serrano; E Gómez-Lahoz; R A DePinho; D Beach; D Bar-Sagi
Journal:  Science       Date:  1995-01-13       Impact factor: 47.728

9.  Alterations of the Rb gene and its association with Ki-ras activation and p53 inactivation in endometrial adenocarcinoma.

Authors:  T Enomoto; M Fujita; M Inoue; A Nakazawa-Miyamoto; O Tanizawa; T Nomura
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

10.  Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer.

Authors:  I E Schauer; S Siriwardana; T A Langan; R A Sclafani
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

View more
  4 in total

1.  The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras.

Authors:  V M Ho; B E Schaffer; A N Karnezis; K S Park; J Sage
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

2.  ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation.

Authors:  Yanfang Wang; Rajamani Rathinam; Amelia Walch; Suresh K Alahari
Journal:  J Biol Chem       Date:  2009-06-22       Impact factor: 5.157

3.  3-Methylcholanthrene, an AhR agonist, caused cell-cycle arrest by histone deacetylation through a RhoA-dependent recruitment of HDAC1 and pRb2 to E2F1 complex.

Authors:  Chih-Cheng Chang; Yuh-Mou Sue; Nian-Jie Yang; Yi-Hsuan Lee; Shu-Hui Juan
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

4.  Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16.

Authors:  Maria C Todd; Thomas A Langan; Robert A Sclafani
Journal:  J Cancer       Date:  2017-01-13       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.